These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 3374263

  • 1. Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors.
    Buckholtz NS, Zhou DF, Freedman DX.
    Life Sci; 1988; 42(24):2439-45. PubMed ID: 3374263
    [Abstract] [Full Text] [Related]

  • 2. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
    Pierce PA, Peroutka SJ.
    J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
    [Abstract] [Full Text] [Related]

  • 3. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
    Buckholtz NS, Zhou DF, Freedman DX, Potter WZ.
    Neuropsychopharmacology; 1990 Apr; 3(2):137-48. PubMed ID: 1969270
    [Abstract] [Full Text] [Related]

  • 4. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M, Lyon RA, Glennon RA.
    Psychopharmacology (Berl); 1988 Apr; 94(2):213-6. PubMed ID: 3127847
    [Abstract] [Full Text] [Related]

  • 5. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist.
    Pranzatelli MR.
    Biochem Pharmacol; 1991 Aug 08; 42(5):1099-105. PubMed ID: 1872895
    [Abstract] [Full Text] [Related]

  • 6. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E, Burris KD, Knoth K.
    J Pharmacol Exp Ther; 1988 Sep 08; 246(3):924-8. PubMed ID: 2843634
    [Abstract] [Full Text] [Related]

  • 7. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand.
    Titeler M, Lyon RA, Davis KH, Glennon RA.
    Biochem Pharmacol; 1987 Oct 01; 36(19):3265-71. PubMed ID: 3663239
    [Abstract] [Full Text] [Related]

  • 8. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives.
    Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE.
    Pharmacol Biochem Behav; 1994 Mar 01; 47(3):667-73. PubMed ID: 8208787
    [Abstract] [Full Text] [Related]

  • 9. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
    Pierce PA, Peroutka SJ.
    Psychopharmacology (Berl); 1989 Mar 01; 97(1):118-22. PubMed ID: 2540505
    [Abstract] [Full Text] [Related]

  • 10. Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites.
    Buchborn T, Schröder H, Dieterich DC, Grecksch G, Höllt V.
    Behav Brain Res; 2015 Mar 15; 281():62-8. PubMed ID: 25513973
    [Abstract] [Full Text] [Related]

  • 11. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain.
    Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB.
    J Pharmacol Exp Ther; 1990 Nov 15; 255(2):843-57. PubMed ID: 2243353
    [Abstract] [Full Text] [Related]

  • 12. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ, Aghajanian GK.
    J Pharmacol Exp Ther; 1996 Sep 15; 278(3):1373-82. PubMed ID: 8819525
    [Abstract] [Full Text] [Related]

  • 13. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis.
    Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M.
    Psychopharmacology (Berl); 1989 Sep 15; 98(4):495-9. PubMed ID: 2505289
    [Abstract] [Full Text] [Related]

  • 14. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD).
    Schindler EA, Dave KD, Smolock EM, Aloyo VJ, Harvey JA.
    Pharmacol Biochem Behav; 2012 Mar 15; 101(1):69-76. PubMed ID: 22197710
    [Abstract] [Full Text] [Related]

  • 15. LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex.
    Arvanov VL, Liang X, Russo A, Wang RY.
    Eur J Neurosci; 1999 Sep 15; 11(9):3064-72. PubMed ID: 10510170
    [Abstract] [Full Text] [Related]

  • 16. Daily LSD administration selectively decreases serotonin2 receptor binding in rat brain.
    Buckholtz NS, Freedman DX, Middaugh LD.
    Eur J Pharmacol; 1985 Mar 12; 109(3):421-5. PubMed ID: 3987809
    [Abstract] [Full Text] [Related]

  • 17. Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells.
    Ferry RC, Unsworth CD, Molinoff PB.
    Mol Pharmacol; 1993 May 12; 43(5):726-33. PubMed ID: 8388988
    [Abstract] [Full Text] [Related]

  • 18. Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment.
    Leysen JE, Janssen PF, Niemegeers CJ.
    Eur J Pharmacol; 1989 Apr 12; 163(1):145-9. PubMed ID: 2545460
    [Abstract] [Full Text] [Related]

  • 19. Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats.
    Krebs KM, Geyer MA.
    Psychopharmacology (Berl); 1994 Jan 12; 113(3-4):429-37. PubMed ID: 7862855
    [Abstract] [Full Text] [Related]

  • 20. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
    Titeler M, Herrick K, Lyon RA, McKenney JD, Glennon RA.
    Eur J Pharmacol; 1985 Oct 29; 117(1):145-6. PubMed ID: 4085543
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.